Jiping Wang, MD
Surgical Oncology · Boston, MANPI 1568608669
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Merck at 42.1% of the total. Reporting peaked in 2024 at $7,656 and has fallen 75.1% since, to $1,903 in 2025.
Across 35 payments — averaging $414.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Histosonics, Inc.$3K
- Intuitive Surgical$2K
- Medtronic$1K
- Covidien LP$906
- Sirtex Medical Inc$159
- plus $470 from 4 others
Across 7 payments — averaging $720,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5M
- Sirtex Medical Inc$46K
What the payments were for
- Consulting fees$9757%
- Speaking & faculty fees$6,40044%
- Travel & lodging$4,53131%
- Food & beverage$1,3439%
- Education$1,2509%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $6,100 |
| Histosonics, Inc. | 7 | $3,459 |
| Intuitive Surgical | 10 | $2,284 |
| Medtronic | 2 | $1,120 |
| Covidien LP | 9 | $906 |
| Sirtex Medical Inc | 2 | $159 |
| Beigene USA, Inc. | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $119 |
| Foundation Medicine, Inc. | 1 | $102 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,768
- ForceTriad$426
- DA VINCI SP$300
- Sonicision$284
- SIR-Spheres Microspheres$150
- BRUKINSA$125
- IMFINZI$125
- Tavalisse$119
- FOUNDATIONONE$102
- FOUNDATIONONE HEME$102
- FOUNDATIONONE CDX$102
- FOUNDATIONFOCUS$102
- FOUNDATIONONE LIQUID$102
How this compares
$14,499 in reported general payments places this provider in the 85th percentile of 55 surgical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Boston
- Thanh BarbieBoston$108K
- Elizabeth MittendorfBoston$73K
- Genevieve BolandBoston$53K
- Eduardo Vega PizarroBoston$46K
- Monica Valero CamachoBoston$30K
- Arthur MoserBoston$12K
- Katherina CalvilloBoston$5K
- Teviah SachsBoston$5K
- Motaz QadanBoston$4K
- Nicole Look-HongBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.